This study investigates the impact of an investigational medication, specifically oral tocotrienol (TCT), on patients with Nonalcoholic Steatohepatitis (NASH) and its potential to reduce the Model for End Stage Liver Disease (MELD) score over time. NASH is a liver condition characterized by inflammation and damage caused by a buildup of fat in the liver. The MELD score is a measure used to assess the severity of chronic liver disease and predict mortality risk.
Participants in this study will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor changes in the MELD score to determine the effectiveness of the investigational medication in slowing down liver disease progression.
- Who can participate: Adults with end-stage liver disease due to NASH, confirmed by a liver biopsy within the past year, are eligible. Participants must not have other causes of liver dysfunction and should be able to communicate in English.
- Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. The placebo is an inactive substance that resembles the investigational medication but contains no active ingredients.
